Agilent (A) AI Stock Analysis

• Market Cap: $33.94B
• Dividend Yield: 0.81%
• Average Volume (3M): 1.72M
• Price to Earnings (P/E): 29.5
• Beta (1Y): 1.02
• Revenue Growth: 0.56%
• EPS Growth: -4.08%
• Country: US
• Employees: 17,900
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.31
• Shares Outstanding: 284,064,730
• 10 Day Avg. Volume: 2,051,531
• 30 Day Avg. Volume: 1,716,650
• PEG Ratio: -4.25
• Price to Book (P/B): 5.55
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 28.54
• Enterprise Value/Market Cap: 1.06
• Enterprise Value/Revenue: 1.37
• Enterprise Value/Gross Profit: 10.17
• Enterprise Value/Ebitda: 4.92
• 1Y Price Target: $136.27
• Price Target Upside: 13.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13

• Rating: 75 Outperform
• Price Target: $134.00 ▲(11.34%Upside)

Agilent's strong financial performance and positive earnings call insights are the most significant factors contributing to the stock score. However, technical indicators and valuation concerns, such as a high P/E ratio and low dividend yield, moderate the overall score. Investors should note the company's strategic initiatives and market growth potential, particularly in diagnostics and PFAS testing.

Positive Factors

Financial Performance

Agilent reaffirmed their FY3Q25 guidance and long-term targets, which should provide some comfort to investors.

Leadership Stability

Rodney Gonsalves, who currently works as corporate controller and principal accounting officer, will serve as interim CFO, ensuring experienced leadership during the transition.

Product Adoption

Strong adoption and uptake of Infinity III LC upgrades reflect a progressing replacement cycle.

Negative Factors

Financial Uncertainty

Agilent did not comment on FY25 guidance, which might lead to uncertainty about the company's future financial performance.

Leadership Uncertainty

Sudden CFO departure at Agilent comes as a surprise.

Market Reaction

The sudden CFO change and FY25 questions are pressuring shares, with A down -5% as of the time of this note.

Agilent Business Overview & Revenue Model

Company Description

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

How the Company Makes Money

Agilent Technologies generates revenue primarily through the sale of scientific instruments and related products. Its revenue streams include the sale of analytical instruments, laboratory software, and consumables. The company also earns from providing installation, maintenance, and training services to its customers. Agilent maintains strategic partnerships and collaborations with various industry leaders and research institutions to enhance its product offerings and expand its market reach. The company's revenue is significantly influenced by investments in research and development, as well as by its ability to adapt to regulatory changes and technological advancements in the sectors it serves.

Agilent Financial Statement Overview

Summary

Agilent demonstrates strong financial performance with high profitability margins and effective cash management. While there are concerns about declining revenue growth and increasing debt, the company's operational efficiency remains robust.

Income Statement

Agilent shows a robust financial performance based on its income statement metrics. The TTM gross profit margin stands at 26.73%, indicating efficient cost management. Despite a slight decline in total revenue from previous periods, the company maintains a strong net profit margin of 17.59% for TTM, reflecting effective operational strategies. The EBIT and EBITDA margins are solid at 21.38% and 21.21%, respectively, showcasing operational efficiency and stable earnings before depreciation. However, revenue growth has slightly declined in recent reports, which could be a potential concern for future growth.

Balance Sheet

The balance sheet indicates a stable financial position with a debt-to-equity ratio of 0.57, suggesting moderate leverage. The equity ratio is healthy at 50.47%, indicating a strong asset base supported by equity. Return on equity is impressive at 19.01%, which is a testament to the company's ability to generate returns for shareholders. However, the slight increase in total debt over periods requires monitoring, as it may impact future leverage and interest obligations.

Cash Flow

Agilent's cash flow statement reflects strong cash generation capabilities. The free cash flow growth rate is positive, and the operating cash flow to net income ratio is 1.36 in the TTM, highlighting effective cash conversion from earnings. The free cash flow to net income ratio is robust at 1.20, emphasizing the company's ability to generate significant free cash flow relative to its net income. These figures suggest healthy cash management practices, though slight fluctuations in operating cash flow should be observed.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.51B	6.83B	6.85B	6.32B	5.34B
Gross Profit	3.54B	3.46B	3.72B	3.41B	2.84B
EBITDA	1.87B	1.70B	1.91B	1.76B	1.23B
Net Income	1.29B	1.24B	1.25B	1.21B	719.00M
Balance Sheet
Total Assets	11.85B	10.76B	10.53B	10.71B	9.63B
Cash, Cash Equivalents and Short-Term Investments	1.33B	1.59B	1.05B	1.57B	1.44B
Total Debt	3.57B	2.90B	2.92B	2.91B	2.54B
Total Liabilities	5.95B	4.92B	5.23B	5.32B	4.75B
Stockholders Equity	5.90B	5.84B	5.30B	5.39B	4.87B
Cash Flow
Free Cash Flow	1.37B	1.47B	1.02B	1.30B	802.00M
Operating Cash Flow	1.75B	1.77B	1.31B	1.49B	921.00M
Investing Cash Flow	-1.26B	-310.00M	-338.00M	-749.00M	-147.00M
Financing Cash Flow	-752.00M	-930.00M	-1.37B	-696.00M	-717.00M

Agilent Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 120.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For A, the sentiment is Positive. The current price of 120.35 is above the 20-day moving average (MA) of 118.61, above the 50-day MA of 115.99, and below the 200-day MA of 126.02, indicating a neutral trend. The MACD of 0.18 indicates Positive momentum. The RSI at 55.59 is Neutral, neither overbought nor oversold. The STOCH value of 60.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for A.

Agilent Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IDXX	79 Outperform	$43.48B	49.96	59.33%	―	5.56%	4.66%
TMO	77 Outperform	$176.18B	27.01	13.46%	0.35%	2.05%	7.03%
A	75 Outperform	$33.94B	29.47	18.88%	0.81%	0.56%	-4.08%
WAT	71 Outperform	$17.77B	27.07	40.82%	―	2.57%	8.31%
DHR	68 Neutral	$141.70B	42.03	6.68%	0.58%	-3.24%	-16.60%
MTD	65 Neutral	$26.13B	31.36	-680.23%	―	1.18%	12.34%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%

Agilent Corporate Events

Agilent CFO Resignation Announced, Interim Replacement Named

On July 11, 2025, Agilent Technologies announced the resignation of Robert W. McMahon, its Senior Vice President and Chief Financial Officer, effective July 31, 2025, due to personal reasons. Rodney Gonsalves, the current Vice President, Corporate Controller, and Principal Accounting Officer, will serve as interim CFO. Agilent remains confident in its long-term plans and expects its third-quarter financial results to align with previous guidance.

The most recent analyst rating on (A) stock is a Hold with a $135.00 price target. To see the full list of analyst forecasts on Agilent stock, see the A Stock Forecast page.

Agilent Expands Board, Appoints Two New Directors

On May 20, 2025, Agilent Technologies announced the expansion of its Board of Directors from 10 to 12 members, appointing Pascal Soriot and Judy Gawlik Brown as new directors. Soriot, CEO of AstraZeneca, and Brown, founder of Downtown Advisory, bring extensive experience in pharmaceuticals, biotechnology, and strategic leadership, which is expected to support Agilent’s growth initiatives. The company also amended its bylaws to streamline decision-making processes. Additionally, Heidi Kunz retired from the Board after over 20 years of service, marking a significant transition in Agilent’s leadership.

The most recent analyst rating on (A) stock is a Hold with a $130.00 price target. To see the full list of analyst forecasts on Agilent stock, see the A Stock Forecast page.